Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC)

Vasilios Karavasilis,Alain C. Mita,Gary R. Hudes,David I. Quinn,Anna C. Ferrari,Ivo Kocák,Anne Keating,P. Bartes,D. Charleston,J.S. de Bono

Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC)

2016

Vasilios Karavasilis
Alain C. Mita
Gary R. Hudes
David I. Quinn
Anna C. Ferrari
Ivo Kocák
Anne Keating
P. Bartes
D. Charleston
J.S. de Bono

5135 Background: In a PC-3 tumor cell model YM155 inhibited survivin mRNA transcription and survivin protein expression and showed potent (nM) anti-proliferation activity with strong signs of tumor...

Keywords:

Hormone refractory prostate cancer
Cell
Messenger RNA
Transcription (biology)
Cancer research
Protein expression
Survivin
Pathology
Medicine
tumor cells
continuous infusion
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations